Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Normalisation of Haemostasis in Haemophilia A

View through CrossRef
Haemophilia A (Factor VIII [FVIII] levels ≤40 IU/dL) is a chronic condition with consequences beyond bleeding complications. Many people with haemophilia A (PwHA) experience pain, joint damage, psychosocial impacts, restrictions in daily activities, and limitations in physical activities. Cédric Hermans, Professor at the Cliniques Universitaires Saint-Luc, Brussels, Belgium, outlined how ambitious treatment goals, beyond converting severe haemophilia A into a more moderate or mild form of the condition, are required. With new treatments, it will be possible to target FVIII activity levels in the non-haemophilia range (>40 IU/dL), allowing PwHA to reach freedom from bleeds, leading to a haemophilia-free mindset, and comparable quality of life (QoL) with their peers. Maria Elisa Mancuso, Senior Haematology Consultant at IRCCS Humanitas Research Hospital, Milan, Italy, highlighted the evolution of haemophilia A treatments; she showed clinical evidence that a zero-bleed goal may require sustained FVIII activity levels >40 IU/dL for complete protection against all types of bleeds and joint damage. Rubén Berrueco, Paediatric Haematologist at the Sant Joan de Déu Barcelona Children’s Hospital, Spain, described the haemophilia paediatric patient journey, and how uncertainties related to bleeds and treatment burden pose unique challenges for children and their caregivers. He presented his perspectives on challenges with current treatments (e.g., delayed inhibitor development, subclinical bleeds, and lack of skills for intravenous administration) and the need to improve self-autonomy and decrease hospital dependency. New treatments to achieve the non-haemophilia range of FVIII could address current unmet needs. The experts discussed that treatments for many diseases (e.g., diabetes, hypertension) aim to restore normal values (blood sugar, blood pressure), which was not the case until now for haemophilia. A more patient-centred approach with treatments targeting normal values of FVIII could allow all PwHA to become mentally and physically liberated from the constraints of their condition, and to live with optimised health and well-being.
European Medical Group
Title: Normalisation of Haemostasis in Haemophilia A
Description:
Haemophilia A (Factor VIII [FVIII] levels ≤40 IU/dL) is a chronic condition with consequences beyond bleeding complications.
Many people with haemophilia A (PwHA) experience pain, joint damage, psychosocial impacts, restrictions in daily activities, and limitations in physical activities.
Cédric Hermans, Professor at the Cliniques Universitaires Saint-Luc, Brussels, Belgium, outlined how ambitious treatment goals, beyond converting severe haemophilia A into a more moderate or mild form of the condition, are required.
With new treatments, it will be possible to target FVIII activity levels in the non-haemophilia range (>40 IU/dL), allowing PwHA to reach freedom from bleeds, leading to a haemophilia-free mindset, and comparable quality of life (QoL) with their peers.
Maria Elisa Mancuso, Senior Haematology Consultant at IRCCS Humanitas Research Hospital, Milan, Italy, highlighted the evolution of haemophilia A treatments; she showed clinical evidence that a zero-bleed goal may require sustained FVIII activity levels >40 IU/dL for complete protection against all types of bleeds and joint damage.
Rubén Berrueco, Paediatric Haematologist at the Sant Joan de Déu Barcelona Children’s Hospital, Spain, described the haemophilia paediatric patient journey, and how uncertainties related to bleeds and treatment burden pose unique challenges for children and their caregivers.
He presented his perspectives on challenges with current treatments (e.
g.
, delayed inhibitor development, subclinical bleeds, and lack of skills for intravenous administration) and the need to improve self-autonomy and decrease hospital dependency.
New treatments to achieve the non-haemophilia range of FVIII could address current unmet needs.
The experts discussed that treatments for many diseases (e.
g.
, diabetes, hypertension) aim to restore normal values (blood sugar, blood pressure), which was not the case until now for haemophilia.
A more patient-centred approach with treatments targeting normal values of FVIII could allow all PwHA to become mentally and physically liberated from the constraints of their condition, and to live with optimised health and well-being.

Related Results

A preliminary application of a haemophilia value framework to emerging therapies in haemophilia
A preliminary application of a haemophilia value framework to emerging therapies in haemophilia
AbstractIntroductionEmergence of new therapies are anticipated to improve clinical outcomes and quality of life of persons with haemophilia. Challenges in conducting randomized cli...
Haemophilia treatment in 2030
Haemophilia treatment in 2030
IntroductionLooking into the future is difficult and sometimes hazardous. A reliable look into haemophilia treatment in 2030 should be based on history and contemporary progress as...
Preventing bleeds by treatment: new era for haemophilia changing the paradigm
Preventing bleeds by treatment: new era for haemophilia changing the paradigm
IntroductionCoagulation products have allowed patients with severe haemophilia to lead a normal life. This is, however, only true for patients who received an early diagnosis and c...
Bioclinical features of haemophilia patients in Benin in 2023: Towards better care
Bioclinical features of haemophilia patients in Benin in 2023: Towards better care
AbstractObjectiveTo analyse the demographic, clinical and laboratory data of Beninese patients with haemophilia.MethodA prospective survey was conducted in three different hospital...
Sexual expression, fulfilment and haemophilia: reflections from the 16th Australian and New Zealand Haemophilia Conference
Sexual expression, fulfilment and haemophilia: reflections from the 16th Australian and New Zealand Haemophilia Conference
Summary.  Following a presentation given at the 16th Australian and New Zealand Haemophilia Conference; Enjoying your sex life: Issues and solutions for men with physical impairmen...
Hemgenix as First Gene Therapy for Treatment of Haemophilia B
Hemgenix as First Gene Therapy for Treatment of Haemophilia B
We know about haemophilia B is an inheritable bleeding complaint performing from missing or inadequate situations of blood clotting Factor IX, a protein demanded to produce blood c...
Utilization of Fresh Frozen Plasma and Cryoprecipitate in Factor VIII and Factor IX Deficient Hemophilia Patient
Utilization of Fresh Frozen Plasma and Cryoprecipitate in Factor VIII and Factor IX Deficient Hemophilia Patient
Haemophilia is one of the most common causes of inherited bleeding disorder resulting from deficiency of coagulation factor VIII or factor IX. Ideally, replacement should be done w...
The optimal mode of delivery for the haemophilia carrier expecting an affected infant is caesarean delivery
The optimal mode of delivery for the haemophilia carrier expecting an affected infant is caesarean delivery
Summary.  While a majority of affected infants of haemophilia carriers who deliver vaginally do not suffer a head bleed, the outcome of labour cannot be predicted. A planned vagina...

Back to Top